Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol Myers Squibb (BMY) was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by delaying federal approval for three drugs, 1-1/2 months after a federal judge abruptly dismissed an earlier version of the case.